Harel Insurance Investments & Financial Services Ltd. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 38.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,880 shares of the company's stock after acquiring an additional 4,370 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned approximately 0.06% of Medpace worth $8,919,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. grew its holdings in shares of Medpace by 439.0% during the 4th quarter. SBI Securities Co. Ltd. now owns 415 shares of the company's stock worth $233,000 after purchasing an additional 338 shares during the period. QRG Capital Management Inc. grew its holdings in shares of Medpace by 15.0% during the 4th quarter. QRG Capital Management Inc. now owns 3,320 shares of the company's stock worth $1,865,000 after purchasing an additional 434 shares during the period. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in shares of Medpace during the 4th quarter worth about $430,000. Pittenger & Anderson Inc. purchased a new stake in shares of Medpace during the 4th quarter worth about $997,000. Finally, PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Medpace during the 4th quarter worth about $1,890,000. 77.98% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Medpace
Here are the key news stories impacting Medpace this week:
- Neutral Sentiment: Multiple law firms are soliciting Medpace investors and reminding potential plaintiffs of lead‑plaintiff deadlines (early June). These notices are procedural (solicitation/reminder) but signal broad interest from plaintiffs’ counsel. Read More.
- Negative Sentiment: At least one class action accuses Medpace and certain officers of securities fraud tied to alleged understatement of cancellation rates and overstatement of book‑to‑bill, and points to a single‑day ~16% stock decline as a market reaction. That lawsuit (and similar filings) could lead to discovery, legal expense, potential settlements or judgments and create near‑term downside pressure. Read More.
- Negative Sentiment: Multiple additional firms (Bronstein, Rosen, Faruqi, Schall, Bragar, Gross, DJS, etc.) have filed or announced investigations and encouraged investors to seek lead‑plaintiff status, increasing the likelihood of consolidated litigation and active pursuit of damages claims. Deadlines to seek leadership are imminent (early June). Read More.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on MEDP shares. Wall Street Zen cut Medpace from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Royal Bank Of Canada decreased their target price on Medpace from $522.00 to $484.00 and set an "outperform" rating for the company in a report on Friday, April 24th. BMO Capital Markets decreased their target price on Medpace from $460.00 to $400.00 and set a "market perform" rating for the company in a report on Friday, April 24th. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and set a $560.00 target price for the company in a report on Friday, February 13th. Finally, TD Cowen upgraded Medpace from a "sell" rating to a "hold" rating and decreased their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $467.08.
Check Out Our Latest Research Report on Medpace
Medpace Stock Performance
Medpace stock opened at $430.32 on Wednesday. The stock's 50 day moving average price is $468.44 and its 200 day moving average price is $532.37. The firm has a market capitalization of $12.29 billion, a PE ratio of 27.05, a price-to-earnings-growth ratio of 2.12 and a beta of 1.19. Medpace Holdings, Inc. has a one year low of $284.10 and a one year high of $628.92.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace's revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, President Jesse J. Geiger sold 31,707 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company's stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 20.50% of the company's stock.
About Medpace
(
Free Report)
Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
See Also
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
